406 related articles for article (PubMed ID: 28703769)
1. Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling.
Metzemaekers M; Mortier A; Janssens R; Boff D; Vanbrabant L; Lamoen N; Van Damme J; Teixeira MM; De Meester I; Amaral FA; Proost P
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703769
[TBL] [Abstract][Full Text] [Related]
2. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
[TBL] [Abstract][Full Text] [Related]
3. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes.
Janssens R; Mortier A; Boff D; Ruytinx P; Gouwy M; Vantilt B; Larsen O; Daugvilaite V; Rosenkilde MM; Parmentier M; Noppen S; Liekens S; Van Damme J; Struyf S; Teixeira MM; Amaral FA; Proost P
Biochem Pharmacol; 2017 May; 132():92-101. PubMed ID: 28322746
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.
Ludwig A; Schiemann F; Mentlein R; Lindner B; Brandt E
J Leukoc Biol; 2002 Jul; 72(1):183-91. PubMed ID: 12101279
[TBL] [Abstract][Full Text] [Related]
6. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
[TBL] [Abstract][Full Text] [Related]
7. Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity.
Dillemans L; Yu K; De Zutter A; Noppen S; Gouwy M; Berghmans N; Verhallen L; De Bondt M; Vanbrabant L; Brusselmans S; Martens E; Schols D; Verschueren P; Rosenkilde MM; Marques PE; Struyf S; Proost P
Cell Commun Signal; 2024 Feb; 22(1):94. PubMed ID: 38308278
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26.
Metzemaekers M; Van Damme J; Mortier A; Proost P
Front Immunol; 2016; 7():483. PubMed ID: 27891127
[TBL] [Abstract][Full Text] [Related]
9. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan.
Soejima K; Rollins BJ
J Immunol; 2001 Dec; 167(11):6576-82. PubMed ID: 11714827
[TBL] [Abstract][Full Text] [Related]
10. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family.
Lambeir AM; Proost P; Durinx C; Bal G; Senten K; Augustyns K; Scharpé S; Van Damme J; De Meester I
J Biol Chem; 2001 Aug; 276(32):29839-45. PubMed ID: 11390394
[TBL] [Abstract][Full Text] [Related]
11. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation.
Loos T; Mortier A; Gouwy M; Ronsse I; Put W; Lenaerts JP; Van Damme J; Proost P
Blood; 2008 Oct; 112(7):2648-56. PubMed ID: 18645041
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.
Cox JH; Dean RA; Roberts CR; Overall CM
J Biol Chem; 2008 Jul; 283(28):19389-99. PubMed ID: 18411283
[TBL] [Abstract][Full Text] [Related]
13. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.
Proost P; Struyf S; Loos T; Gouwy M; Schutyser E; Conings R; Ronsse I; Parmentier M; Grillet B; Opdenakker G; Balzarini J; Van Damme J
Arthritis Res Ther; 2006; 8(4):R107. PubMed ID: 16846531
[TBL] [Abstract][Full Text] [Related]
14. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
15. Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity.
Hensbergen PJ; van der Raaij-Helmer EM; Dijkman R; van der Schors RC; Werner-Felmayer G; Boorsma DM; Scheper RJ; Willemze R; Tensen CP
Eur J Biochem; 2001 Sep; 268(18):4992-9. PubMed ID: 11559369
[TBL] [Abstract][Full Text] [Related]
16. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
Stanford MM; Issekutz TB
J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
[TBL] [Abstract][Full Text] [Related]
18. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.
Colvin RA; Campanella GS; Manice LA; Luster AD
Mol Cell Biol; 2006 Aug; 26(15):5838-49. PubMed ID: 16847335
[TBL] [Abstract][Full Text] [Related]
19. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction.
Proost P; Struyf S; Schols D; Opdenakker G; Sozzani S; Allavena P; Mantovani A; Augustyns K; Bal G; Haemers A; Lambeir AM; Scharpé S; Van Damme J; De Meester I
J Biol Chem; 1999 Feb; 274(7):3988-93. PubMed ID: 9933589
[TBL] [Abstract][Full Text] [Related]
20. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist.
Proost P; Menten P; Struyf S; Schutyser E; De Meester I; Van Damme J
Blood; 2000 Sep; 96(5):1674-80. PubMed ID: 10961862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
